Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-10-21

Clinical Trial Update: Open-Label of SPN-820 in Adults With Major Depressive Disorder [Phase 2]

View source ↗

Summary

A Phase 2 open-label study of SPN-820 in adults with major depressive disorder has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SPN-820

Snippet

Sponsor: Navitor Pharmaceuticals, Inc. | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED | Results posted: 2025-10-21